JVC Dismisses Deputy General Director Nguyen Dai Nam After Nine Months

Overview

Viet Nhat Medical Investment and Development JSC (HOSE: JVC) has dismissed Deputy General Director Nguyen Dai Nam effective 15 October 2026, according to a company announcement of a General Director decision. The stated reason is a rearrangement of the company’s management apparatus. The change lands while JVC shares trade near historic lows and remain under a HoSE warning, making governance stability the central question for holders.

Key Facts

• Nguyen Dai Nam was dismissed as Deputy General Director effective 15 October 2026, per a General Director decision disclosed by JVC.
• Nam had been appointed to the role on 20 January 2026, meaning he left after less than nine months.
• The company cited “sắp xếp bộ máy quản lý” (management apparatus restructuring) as the reason.
• Nam is required to hand over outstanding work, documents and company assets to a person designated by the General Director.
• JVC shares closed at VND 2,940 on 16 October 2026, up more than 4% on the session but more than 50% below the early-2026 price range.
• HoSE kept JVC under warning status, citing undistributed after-tax profit of more than VND 929 billion as of 30 June 2026 under the reviewed half-year financial statements.
• H1 2026 revenue was nearly VND 302 billion, down 5% year on year, while net profit attributable to parent shareholders reached just over VND 28 billion, up 2%.

What Happened

JVC published a decision by its General Director removing Nguyen Dai Nam from the Deputy General Director post with effect from 15 October 2026. The announcement states the dismissal is part of a reorganization of the company’s management structure. Under the decision, Nam must transfer pending work, documents and assets in his possession to a person appointed by the General Director, in line with company rules and applicable law.

The disclosure highlights the brevity of Nam’s tenure: he was appointed Deputy General Director on 20 January 2026 and exited in under nine months. The announcement does not name a replacement, does not disclose any severance or settlement terms, and does not quantify the financial impact of the change. JVC, founded in 2001 as Viet Nhat Medical Equipment Company Limited, supplies, leases, installs and maintains medical equipment, with a stated strength in diagnostic imaging and services for hospitals and healthcare facilities. It has been listed on HoSE since June 2011.

Market Context

JVC trades on the HoSE and closed at VND 2,940 on 16 October 2026, a gain of more than 4% on the day but still more than 50% below its early-2026 range. The shares remain under a HoSE warning, which the exchange maintained because undistributed after-tax profit stood at more than VND 929 billion as of 30 June 2026 in the reviewed half-year statements. H1 2026 revenue of nearly VND 302 billion fell 5% year on year, though gross profit rose 21% to almost VND 93 billion as cost of goods sold declined faster. Financial expenses more than doubled to nearly VND 14 billion, with interest expense rising from VND 5 billion to almost VND 14 billion, roughly tripling year on year. Net profit after tax was more than VND 27.2 billion, down nearly 1%.

Strategic Significance

The departure of a deputy general director after less than nine months, framed as internal restructuring, raises questions about management continuity at a company already flagged by the exchange. For long-term holders, the core thesis in JVC rests on its diagnostic imaging franchise and hospital equipment servicing, not on a single executive. But repeated, short-tenure leadership changes can slow procurement cycles, hospital contract renewals and capital allocation decisions, at a time when rising interest costs are already compressing earnings. The HoSE warning tied to accumulated undistributed profit adds a separate structural overhang that management stability would normally help address.

What to Watch

• Any JVC disclosure naming a replacement Deputy General Director or a broader board and executive reshuffle.
• HoSE updates on JVC’s warning status and any required remediation timeline.
• Q3 2026 financial statements, particularly interest expense and gross margin trends.
• The reviewed half-year figures behind the VND 929 billion undistributed profit balance and any plan to address it.
• Further senior management or board changes that would confirm or contradict the restructuring rationale.